- Home
- ESS vs GMAB Comparison
ESS vs GMAB Comparison
Compare ESS & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESS
- GMAB
- Stock Information
- Founded
- ESS 1971
- GMAB 1999
- Country
- ESS United States
- GMAB Denmark
- Employees
- ESS N/A
- GMAB N/A
- Industry
- ESS Real Estate Investment Trusts
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- ESS Real Estate
- GMAB Health Care
- Exchange
- ESS Nasdaq
- GMAB Nasdaq
- Market Cap
- ESS 16.9B
- GMAB 17.4B
- IPO Year
- ESS 1994
- GMAB N/A
- Fundamental
- Price
- ESS $262.14
- GMAB $30.40
- Analyst Decision
- ESS Hold
- GMAB Strong Buy
- Analyst Count
- ESS 18
- GMAB 6
- Target Price
- ESS $293.91
- GMAB $40.40
- AVG Volume (30 Days)
- ESS 572.7K
- GMAB 2.6M
- Earning Date
- ESS 10-29-2025
- GMAB 11-06-2025
- Dividend Yield
- ESS 3.93%
- GMAB N/A
- EPS Growth
- ESS 53.64
- GMAB 132.41
- EPS
- ESS 13.15
- GMAB 25.10
- Revenue
- ESS $1,916,711,000.00
- GMAB $3,845,670,022.00
- Revenue This Year
- ESS $4.02
- GMAB $24.92
- Revenue Next Year
- ESS $3.80
- GMAB $15.97
- P/E Ratio
- ESS $19.91
- GMAB $1.21
- Revenue Growth
- ESS 9.37
- GMAB 29.57
- 52 Week Low
- ESS $243.25
- GMAB $17.24
- 52 Week High
- ESS $316.29
- GMAB $33.65
- Technical
- Relative Strength Index (RSI)
- ESS 54.23
- GMAB 57.24
- Support Level
- ESS $256.01
- GMAB $28.08
- Resistance Level
- ESS $261.51
- GMAB $29.35
- Average True Range (ATR)
- ESS 5.91
- GMAB 0.69
- MACD
- ESS 0.83
- GMAB -0.07
- Stochastic Oscillator
- ESS 81.20
- GMAB 98.73
About ESS Essex Property Trust Inc.
Essex Property Trust owns a portfolio of 258 apartment communities with over 62,000 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.